Ravidasvir hydrochloride is a Small Molecule owned by Presidio Pharmaceuticals, and is involved in 16 clinical trials, of which 15 were completed, and 1 is ongoing.

Ravidasvir hydrochloride is a selective inhibitor of NS5A. NS5A is involved in genomic RNA replication. Replicons consist of bicistronic RNA transcripts in which the HCV IRES drives translation of neomycin phosphotransferase; a second IRES [from encephalomyocarditis virus (EMCV)] drives translation of NS3–NS5B. The rapid mutation rate due to the error-prone nature of NS5B and the limited range of cells that support replicon replication of HCV RNA replication and plays a key role for NS5A in this process. PPI-668 targets NS5A protein and inhibits the viral replication.

The revenue for Ravidasvir hydrochloride is expected to reach a total of $594m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Ravidasvir hydrochloride NPV Report.

Ravidasvir hydrochloride was originated by XTL Biopharmaceuticals and is currently owned by Presidio Pharmaceuticals. Ascletis Pharma is the other company associated in development or marketing of Ravidasvir hydrochloride.

Ravidasvir hydrochloride Overview

Ravidasvir Hydrochloride (Asclevir) is a antiviral agent. It is formulated as tablets for oral route of administration. Asclevir is indicated for the treatment of hepatitis C virus infection.

Ascletis Pharma Overview

Ascletis Pharma is a medical company that develops and commercializes novel drugs for unmet medical needs. The company is investigating ASC09 inhibitor to treat HIV type-1 infections; and ASC06, a novel drug for the treatment of liver cancer through RNA interference. It is also advancing products against COVID-19 and fatty liver diseases. Ascletis Pharma utilizes anti-viral and RNAi platform to develop its pipeline products. The company works in partnership with Roche Holding AG; Presidio Networked Solutions LLC; Medivir AB; Janssen Pharmaceutical NV; and Alnylam Pharmaceuticals Inc for developing its products. Ascletis Pharma is headquartered in Hangzhou, Zhejiang, China.

The company reported revenues of (Renminbi) CNY76.9 million for the fiscal year ended December 2021 (FY2021), compared to a revenue of CNY35 million in FY2020. The operating loss of the company was CNY181 million in FY2021, compared to an operating loss of CNY195.4 million in FY2020. The net loss of the company was CNY199 million in FY2021, compared to a net loss of CNY209.2 million in FY2020.

Quick View – Ravidasvir hydrochloride

Report Segments
  • Innovator (NME)
Drug Name
  • Ravidasvir hydrochloride
Administration Pathway
  • Oral
Therapeutic Areas
  • Infectious Disease
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.